Kornimate/medical-research-clean huggingface dataset:
examining the effect of a digital medical device for cognitive and musical training in children with reading disabilities

Conditions: Learning Disorders, Specific; Learning Disabilities; Specific Learning Disorder, With Impairment in Reading; Dyslexia

Summary: the goal of this clinical trial is to assess the effect on reading skills of the digital medical device poppins clinical for cognitive and musical training in pediatric participants (ages 7-11) with a specific learning disability with reading deficit. the main objective of the study is to assess the evolution in reading skills through a word reading task before and after the intervention. participants will be asked to train with the digital medical device poppins clinical 5 times per week for 8 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of sld with reading deficit, based on a speech-language assessment. sld with reading deficit is defined in the diagnostic and statistical manual of mental disorders (dsm-5-tr, 2022) and the international classification of diseases (icd-11, 2022). the speech-language assessment should consist of at least three reading and/or transcription tests with a sd (standard deviation) of at least - 1.4 or a result below the 20th percentile or two reading and/or transcription tests with a sd of at least - 2 sd or a results below the 10th percentile; * subject aged between 7 and 11, enrolled from ce1 to cm2; * french mother tongue or french bilingualism at home and more than 3 years schooling in france; * tablet or smartphone available at home; * subject affiliated to the french national insurance (securite sociale) * subject and parental/legal guardians consent to participate, and commitment to follow the protocol. exclusion criteria: * subject has previously used poppins clinical or mila-learn; * uncontrolled chronic illness (at investigator's discretion); * previous epileptic seizures; * participant actively participating in an interventional study that may affect results.
a study of 2 doses of eye103 compared with ranibizumab (0.5 mg) in participants with dme

Conditions: Diabetic Macular Edema (DME)

Summary: eye-res-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of eye103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (dme). in the first year, all 3 treatment groups will be treated every 4 weeks with either eye103 or ranibizumab. beginning at year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. approximately 960 participants will be entered in the study.

eye-res-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of eye103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (dme). approximately 960 participants will be entered in the study. participants will be randomized 1:1:1 to receive low dose eye103, high dose eye103, or 0.5 mg ranibizumab, administered via intravitreal injection. in the first year, all 3 treatment groups will be treated every 4 weeks with either eye103 or ranibizumab. beginning at year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (pti) algorithm. throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of etdrs bcva, examination by slit-lamp biomicroscopy, fundoscopy, and sd-oct. among other parameters, sd-oct will be used to measure central subfield thickness (cst) in microns.

Eligibility criteria:
inclusion criteria * be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity * be male or female ≥18 years of age. * have type 1 or type 2 diabetes mellitus and a hba1c of ≤12%. * have a decrease in vision in the study eye determined by the investigator to be primarily the result of dme. exclusion criteria: * be pregnant or breastfeeding * history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening * have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (yag) laser capsulotomy within 90 days of screening * are currently using drugs with known retinal toxicity (e.g., hydroxychloroquine, pentosan polysulfate sodium, and amiodarone) * if treatment-experienced for dme have a history of any of the following treatments within the noted time windows: * have had prior treatment with 8 mg aflibercept (eylea hd) or faricimab (vabysmo) within 120 days prior to the screening visit in the study eye * have had an ivt with other anti-vegf treatments (ranibizumab, bevacizumab, aflibercept \[2 mg\], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the screening visit

Keywords: diabetic macular edema dme
kinetics of surfactant proteins, phosphatidylcholine and body water in intensive care unit (icu)

Conditions: ARDS; Sepsis Syndrome

Summary: analysis of kinetics of phosphatidylcholine and specific surfactant proteins, total body water and water turnover in patients with acute respiratory distress syndrome (ards) and in intensive care unit (icu) patients by using non radioactive isotopes as deuterium and carbon-13.

patients with adult respiratory distress syndrome (ards) have low concentrations of disaturated-phosphatidylcholine and surfactant protein-b and c in bronchoalveolar lavage fluid and altered fluid metabolism. injection of stable isotopes such as 13 carbon leucine and deuterated water allows the analysis of disaturated-phosphatidylcholine and surfactant protein-b and c kinetics, total body water and water turnover in patients with ards and in human adults with normal lungs (controls).

Eligibility criteria:
inclusion criteria: inclusion criteria were: * adult patients older than 18 years * expected intensive care unit (icu) length of stay greater than 120 hours from the onset of acute respiratory failure, defined according to the acute respiratory syndrome (ards) berlin criteria or patients admitted for acute neurological failure defined as glasgow coma scale \< 8. * all patients with ards also had sepsis syndrome or septic shock according to the surviving sepsis campaign criteria at the admission to the icu, while no patients with acute neurological failure was septic. at the start of the study, patients with ards/sepsis fulfilled also the following criteria: * start of the study within 72 hours from the onset of the respiratory failure; * stable hemodynamic conditions, defined as no need of fluid boluses for at least 6 hours before the start of the study; * serum urea and creatinine within the normal ranges. patients with acute neurological failure fulfilled the following inclusion criteria: * normal chest radiograph; * arterial partial pressure of oxygen / fraction of inspired oxygen (pao2/fio2) \>300; * no evidence of sepsis, according to body temperature, c reactive protein, white cell count and differential count within normal ranges; * intubation and mechanical ventilation started within 72 h before the beginning of the study. exclusion criteria: exclusion criteria for all study subjects were: * presence of liver failure or renal failure (transaminases \> 3 and creatinine \> 2 times the normal values), * burns \> 30% of body surface bone marrow or lung transplantation, * need of fluid boluses to maintain hemodynamic conditions during the study or extracorporeal circulatory support.
femoral versus psoas continuous peripheral nerve blocks following hip arthroplasty

Conditions: Hip Arthroplasty; Hip Pain

Summary: the purpose of this research study is to determine if the insertion site of a perineural catheter, or tiny tube placed next to the nerves that go to the hip which you will have surgery, affects the amount of pain relief that is experienced after surgery.

to determine the association between perineural catheter location and postoperative analgesia, analgesic requirements, ambulatory distance, and flexion following hip arthroplasty. primary hypothesis: differing the catheter insertion site (femoral vs. psoas compartment) for a perineural local anesthetic infusion is not associated with lower pain scores during the 24-hour period beginning the morning following hip arthroplasty.

Eligibility criteria:
inclusion criteria: * primary, unilateral hip arthroplasty or hip resurfacing * age greater than or equal to 18 years * postoperative analgesic plan includes perineural local anesthetic infusion exclusion criteria: * morbid obesity (bmi greater than 40) * chronic, high-dose opioid use * history of opioid abuse * pregnancy * incarceration * amu meirp-muscular deficit of the ipsilateral femoral nerve and/or quadriceps muscle * inability to communicate with hospital staff

Keywords: pain hip resurfacing catheter nerve block ucsd hip surgery psoas femoral ambulation hip flexion infusion
kanagawa valsartan trial (kvt): effects of valsartan on renal and cardiovascular disease

Conditions: Chronic Kidney Disease; Hypertension

Summary: the purpose of this study is to prove the hypothesis that the progression of renal and cardiovascular disease is more efficiently prevented when the angiotensin ii receptor blocker valsartan is added to conventional antihypertensive therapy.

it is widely recognized that suppression of the renin-angiotensin system ameliorates progression of chronic kidney disease (ckd) and that ckd is an important risk factor for development of cardiovascular disease. however, it has not been fully clarified if amelioration of ckd leads to the lower incidence of cardiovascular disease. the purpose of this study is to determine whether the angiotensin ii receptor antagonist valsartan, in combination with conventional antihypertensive therapy, will ameliorate progression of both ckd and cardiovascular disease. the primary outcome is courses of renal and cardiac function. the secondary outcome is a composite of a doubling of serum creatinine concentration, end-stage renal disease, myocardial infarction, coronary revascularization, stroke, hospitalization for unstable angina, hospitalization for heart failure or death from cardiovascular causes.

Eligibility criteria:
inclusion criteria: * ckd with serum creatinine more than 2.0 mg/dl * blood pressure more than 130/85 mmhg * 20 years old or above exclusion criteria: * end-stage renal disease with maintenance dialysis * polycystic kidney disease * collagen disease * malignant or accelerated hypertension

Keywords: ckd chronic kidney disease hypertension angiotensin ii receptor blocker cardiovascular disease valsartan kvt
copy number variations, inflammatory cytokines and the risk of dementia

Conditions: Dementia

Summary: assess the association of copy number variation (cnv) and inflammatory cytokine with the risk of dementia.

this is a hospital-based case-control study. we plan to assess the association of cnv and inflammatory cytokine with the risk of dementia. hopefully to find some genetic biomarkers to identify the risk of dementia at an early stage.

Eligibility criteria:
inclusion criteria: * hospital recruited dementia patients and controls
guided surgery versus sinus graft

Conditions: Edentulous

Summary: the objective of this study is to compare two surgical procedure to place implant in severely resorbed posterioir part of the maxilla.


Eligibility criteria:
inclusion criteria: * 18 years and more * sinus lift * enough remaining bone for image guided implant placement exclusion criteria: * pregnancy * chronic disease

Keywords: guided surgery sinus graft
cancer driving mutations in endometriosis lesions and development of progesterone resistance

Conditions: Endometriosis; Endometrial Diseases

Summary: this study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic endometrium.

tissues from 100 patients with endometriosis will be analyzed with droplet digital pcr (ddpcr) targeted sequencing and responders (n=50) will be compared to non-responders (n=50) after controlling confounding factors. from a subset of the 100 cases, whole exome sequencing (wes) and methylation-specific pcr (msp)-based methylation profiling on microdissected epithelium and stroma will be performed in matched eutopic and ectopic tissues from 20 patients with known cancer-associated mutations or 20 controls.

Eligibility criteria:
inclusion criteria: * signed informed consent. * gender: female. * age: 18-45 years at the time of signing consent. * clinical or surgical diagnosis of endometriosis undergoing laparoscopy. * controls may not have clinical or surgical diagnosis of endometriosis. * regular menstrual cycles. * bmi between 18-40 kg/m2. * sexually active or have had a previous vaginal exam that used a speculum. * english speaking exclusion criteria: * use of any kind of steroidal therapy including oral contraceptives, norplant, estrogen replacement/supplemental therapy, androgens (danazol, cyclomen, danocrine, testosterone) or progesterone. she may not be taking or be on celebrex. * pregnant. * presence of pelvic infection. * mullerian anomalies with absence of a cervix. * history of cancer of the reproductive tract. * presence of undiagnosed uterine bleeding. * treatment with intrauterine device (iud) or progestin-containing intrauterine device.

Keywords: endometriosis
effect on wound healing of vigamox versus cravit

Conditions: Cataract Extraction

Summary: the purpose of this study was to compare the effects of vigamox and cravit on corneal wound healing after cataract surgery.


Eligibility criteria:
inclusion criteria: * patients of any race and either sex, and over the age of 18, who are scheduled for removal of a cataract and implantation of a posterior chamber intraocular lens using clear corneal incisions or near-clear corneal incisions. * intraocular pressure (iop) readings, treated or untreated, less than or equal to 20 mmhg prior to surgery. glaucoma patients are eligible if an ocular hypotensive agent (only one) controls their iop. * other than cataracts, have normal healthy eyes as determined by the ophthalmic examination and case history. * subconjunctival injections right after cataract surgery are allowed. * other protocol-defined inclusion criteria may apply. exclusion criteria: * any cataract wound that is stitched or any gross abrasion of the epithelium after removal of a cataract and implantation of a posterior chamber intraocular lens. * fluorescein staining of the cornea at baseline. * history or evidence of ocular or systemic disease, which would preclude participation in this study. examples could include autoimmune disease affecting the cornea as well as any corneal dystrophies. * history of ocular inflammatory disease, ocular herpes infection, iritis, uveitis, or sjögren's syndrome. * known or suspected allergy or hypersensitivity to levofloxacin or any related medicines, such as cinoxacin (cinobac), ciprofloxacin (cipro or ciloxan), norfloxacin (chibroxin or noroxin), ofloxacin (floxin), or nalidixic acid (neggram), preservatives, dyes, or any components of the study medication. * treatment for an ocular infection within 30 days prior to study entry. * use of topical or systemic steroids within 7 days prior to study entry. * use of topical anti inflammatory drugs within 7 days prior to study entry. * pregnancy, nursing/lactation, or inadequate birth control methods. oral contraceptives are allowed. * patients with uncontrolled diabetes and/or diabetic retinopathy. * no ointment is used after cataract surgery. * other protocol-defined exclusion criteria may apply.

Keywords: cataract, cornea, vigamox, cravit
exercise testing in icu survivors to evaluate icu-acquired weakness

Conditions: ICU Acquired Weakness; Microvascular Dysfunction; Sepsis; Shock

Summary: this study aims to investigate how sepsis and shock can impair microcirculation in intensive care unit (icu) patients, which can lead to long-lasting muscle weakness/dysfunction or icu-acquired weakness (icu-aw) and exercise limitations.

this longitudinal study will assess microvascular function through four (4) follow-ups after icu discharge: at (i) 7 days, (ii) 3 months, (iii) 6 months, and (iv) 12 months. the goal is to understand how microvascular dysfunction contributes to icu-aw and long-term exercise limitation in icu survivors. specific goals are: 1. characterize the natural trajectory of skeletal muscle microvascular function in icu survivors using high-resolution nirs. 2. demonstrate an impairment in skeletal muscle microvascular oxygen delivery and cardiovascular blood flow regulation in icu survivors.

Eligibility criteria:
inclusion criteria: * patients who have received mechanical ventilation for at least 7 days in the micu or sicu and have subsequently been discharged. * patients enrolled in existing microvascular monitoring study in the icu regardless of duration of mechanical ventilation. exclusion criteria: * unable to provide consent * trajectory of health expected to be significantly limited in the upcoming 12 months

Keywords: exercise limitation icu survivors oxygen delivery nirs microcirculation
effect of trunk stabilization exercises on quality of life and communication in cerebral palsy

Conditions: Cerebral Palsy

Summary: to investigate the effectiveness of neck and trunk stabilization exercises on communication and quality of life (qol) in children with cerebral palsy (cp) with oral motor problems. children with cp were randomly divided into study group (sg) and control group (cg). neurodevelopmental treatment (ndt) approaches and oral motor therapy were applied to both groups. sg also received neck-trunk stabilization training.

in the multidisciplinary approach, special approaches to secondary problems, oral-motor trainings and communication studies are used in addition to neurodevelopment treatment approach in the treatment of children with cp. because of their impact on postural control, neck-trunk stabilization exercises are very important for therapeutic interventions designed to improve quality of life with activities of daily living. as the increases in neck muscle strength are related to trunk stabilization, trunk stabilization exercises are thought to have positive effects on neck muscle strength. in addition, since the neck and trunk are complementary to each other, it is supported by the literature that neck stabilization exercises and trunk stabilization exercises should be applied together.

Eligibility criteria:
inclusion criteria: * 1.5 years and older, * lack of cooperation problem to prevent communication, * to have been diagnosed with cerebral palsy and admitted to the hospital for routine control, * volunteer to participate in the research, * existence of at least one of the items of the "key questions" interrogation system showing feeding/swallowing problems in children with cerebral palsy. exclusion criteria: * presence of severe vision and hearing loss, * use any pharmacological agent to inhibit spasticity, * he/she had undergone orthopedic surgery or botulinum toxin-a injection in the last six months.

Keywords: trunk stabilization exercises oral motor quality of life communication
serologic response to the sars-cov-2 (covid-19) mrna-1273 vaccine in select subsets of oncology patients

Conditions: Covid19; Cancer

Summary: to explore the immune response to the covid-19 vaccine in cancer patients and compare to the general population.

the purpose of this study is to measure the immune response to the covid-19 vaccine in cancer patients and compare to the general population. this information can help optimize the timing of the mrna-1273 vaccine relative to starting treatment for cancer, adding booster immunizations or incorporation of medications that to enhance the immune response.

Eligibility criteria:
inclusion criteria: * subjects are between 50 and 75 years of age; * have not had known or suspected infection with sars-cov-2 at any time; * subjects must fall into one of the following subsets of cancer patients: * localized prostate cancer on radiotherapy or have completed radiotherapy in the last three months * prostate cancer on androgen-deprivation therapy for biochemical recurrence * colon cancer on adjuvant chemotherapy for stage iii disease * cll on a btk inhibitor as a first-line single agent for at least 3 months * melanoma patients on adjuvant immunotherapy with pd-1 checkpoint inhibitors for at least 3 months * have received both doses of sars-cov-2 mrna-1273 vaccine with proof of vaccination or are scheduled to do so; * have at least a one-year life expectancy; * prior radiation therapy is allowed, as long as it was completed more than 6 months prior to vaccination exclusion criteria: * subjects have a known hypersensitivity to a vaccine component; * have had known or suspected infection with sars-cov-2 at any time; * are organ transplant recipient on immunosuppression; * had received or are scheduled to receive a live virus vaccine in the period from 4 weeks prior to dose 1 through 28 days post second dose; * had received or are scheduled to receive an inactivated vaccine in the period ranging from 7 days prior to dose 1 through 7 days post second dose; * received high-dose corticosteroids at any time after receiving the vaccine; * are unable to give informed consent; * are receiving treatment for cll with another agent (such as rituximab) in addition to a btk inhibitor

Keywords: covid19 cancer
comparison of targeting methods for transcranial magnetic stimulation treatment of depression

Conditions: Depression

Summary: we aim to learn whether use of a mixed reality device for transcranial magnetic stimulation (tms) targeting can improve treatment outcomes compared to targeting through scalp measurements or a commercial neuronavigation system. prior studies indicate that neuronavigation can lead to improved treatment outcomes compared to scalp measurements, but neuronavigation adaption has been lacking due to the increased burden of the neuronavigation setup on the tms operator. we will assess whether use of a mixed reality device can decrease that burden and speed up the neuronavigation process and is feasible to be used in a clinical setting.

prior studies suggest that treatment efficacy for tms treatment of depression is affected by the targeting method used to guide tms coil placement. we will compare the treatment outcome for three patient groups. tms coil placement is guided for group 1) with simple scalp measurement targeting, for group 2) with a mixed reality neuronavigation system. the treatment schedule for the medically prescribed tms treatment for each patient are 30 daily weekday repetitive tms treatments for 6 weeks with an additional 6 treatments tapered over 3 weeks.

Eligibility criteria:
inclusion criteria: 1. male or female subjects ages 18-75. 2. mri scanning eligibility, including no evidence of any form of metal embedded in the body (e.g., metal wires, nuts, bolts, screws, plates, sutures), as these produce artifacts when brain imaging. all potential subjects for the mri component will need to successfully complete the screening forms at the stanford center for cognitive and neurobiological imaging (cni) or the lucas center. those subjects who present no contraindications to being scanned will be allowed to participate. 3. healthy subjects with no history of any axis i psychiatric disorder, are taking psychotropic medication, or use illicit drugs. 4. clinical subjects with a diagnosis of treatment resistant depression and prescribed a clinical course of treatment with rtms. exclusion criteria: 1. any contraindication to being scanned in the 3.0t scanner at the lucas center or cni such as having a pacemaker or implanted device that has not been cleared for scanning at 3.0 tesla. 2. history of neurological disorders including but not limited to brain surgery, deep brain stimulation, radiation treatment, brain hemorrhage or tumor, stroke, seizures or epilepsy, head trauma.